CN111840115A - Procyanidine oligomer-based facial hormone-dependent dermatitis treatment liquid and preparation method thereof - Google Patents
Procyanidine oligomer-based facial hormone-dependent dermatitis treatment liquid and preparation method thereof Download PDFInfo
- Publication number
- CN111840115A CN111840115A CN202010827872.0A CN202010827872A CN111840115A CN 111840115 A CN111840115 A CN 111840115A CN 202010827872 A CN202010827872 A CN 202010827872A CN 111840115 A CN111840115 A CN 111840115A
- Authority
- CN
- China
- Prior art keywords
- solution
- stirring
- procyanidin
- oligomer
- dependent dermatitis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000005556 hormone Substances 0.000 title claims abstract description 66
- 229940088597 hormone Drugs 0.000 title claims abstract description 66
- 201000004624 Dermatitis Diseases 0.000 title claims abstract description 63
- 230000001815 facial effect Effects 0.000 title claims abstract description 62
- 238000011282 treatment Methods 0.000 title claims abstract description 62
- 230000001419 dependent effect Effects 0.000 title claims abstract description 59
- 239000007788 liquid Substances 0.000 title claims abstract description 58
- 238000002360 preparation method Methods 0.000 title claims abstract description 7
- XFZJEEAOWLFHDH-UHFFFAOYSA-N (2R,2'R,3R,3'R,4R)-3,3',4',5,7-Pentahydroxyflavan(48)-3,3',4',5,7-pentahydroxyflavan Natural products C=12OC(C=3C=C(O)C(O)=CC=3)C(O)CC2=C(O)C=C(O)C=1C(C1=C(O)C=C(O)C=C1O1)C(O)C1C1=CC=C(O)C(O)=C1 XFZJEEAOWLFHDH-UHFFFAOYSA-N 0.000 claims abstract description 70
- CWEZAWNPTYBADX-UHFFFAOYSA-N Procyanidin Natural products OC1C(OC2C(O)C(Oc3c2c(O)cc(O)c3C4C(O)C(Oc5cc(O)cc(O)c45)c6ccc(O)c(O)c6)c7ccc(O)c(O)c7)c8c(O)cc(O)cc8OC1c9ccc(O)c(O)c9 CWEZAWNPTYBADX-UHFFFAOYSA-N 0.000 claims abstract description 70
- MOJZMWJRUKIQGL-FWCKPOPSSA-N Procyanidin C2 Natural products O[C@@H]1[C@@H](c2cc(O)c(O)cc2)Oc2c([C@H]3[C@H](O)[C@@H](c4cc(O)c(O)cc4)Oc4c3c(O)cc(O)c4)c(O)cc(O)c2[C@@H]1c1c(O)cc(O)c2c1O[C@@H]([C@H](O)C2)c1cc(O)c(O)cc1 MOJZMWJRUKIQGL-FWCKPOPSSA-N 0.000 claims abstract description 70
- 229920002414 procyanidin Polymers 0.000 claims abstract description 70
- HGVVOUNEGQIPMS-UHFFFAOYSA-N procyanidin Chemical compound O1C2=CC(O)=CC(O)=C2C(O)C(O)C1(C=1C=C(O)C(O)=CC=1)OC1CC2=C(O)C=C(O)C=C2OC1C1=CC=C(O)C(O)=C1 HGVVOUNEGQIPMS-UHFFFAOYSA-N 0.000 claims abstract description 67
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 claims abstract description 32
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims abstract description 32
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 claims abstract description 32
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 claims abstract description 32
- 229920001661 Chitosan Polymers 0.000 claims abstract description 30
- 239000008367 deionised water Substances 0.000 claims abstract description 27
- 229910021641 deionized water Inorganic materials 0.000 claims abstract description 27
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 27
- 230000001225 therapeutic effect Effects 0.000 claims abstract description 24
- 239000003906 humectant Substances 0.000 claims abstract description 19
- 238000000034 method Methods 0.000 claims abstract description 19
- 229920001184 polypeptide Polymers 0.000 claims abstract description 19
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 19
- 102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 19
- 229930003427 Vitamin E Natural products 0.000 claims abstract description 16
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims abstract description 16
- 238000002156 mixing Methods 0.000 claims abstract description 16
- 235000019165 vitamin E Nutrition 0.000 claims abstract description 16
- 229940046009 vitamin E Drugs 0.000 claims abstract description 16
- 239000011709 vitamin E Substances 0.000 claims abstract description 16
- 229940069521 aloe extract Drugs 0.000 claims abstract description 14
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 13
- 239000002131 composite material Substances 0.000 claims abstract description 13
- 239000001525 mentha piperita l. herb oil Substances 0.000 claims abstract description 13
- 235000019477 peppermint oil Nutrition 0.000 claims abstract description 13
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 claims abstract description 9
- 108010024636 Glutathione Proteins 0.000 claims abstract description 4
- 229960003180 glutathione Drugs 0.000 claims abstract description 4
- 239000000203 mixture Substances 0.000 claims abstract description 3
- 239000000243 solution Substances 0.000 claims description 119
- 238000003756 stirring Methods 0.000 claims description 91
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 54
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 33
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 claims description 28
- 238000001816 cooling Methods 0.000 claims description 25
- 239000004367 Lipase Substances 0.000 claims description 24
- 102000004882 Lipase Human genes 0.000 claims description 24
- 108090001060 Lipase Proteins 0.000 claims description 24
- 235000019421 lipase Nutrition 0.000 claims description 24
- 238000010438 heat treatment Methods 0.000 claims description 14
- 239000002994 raw material Substances 0.000 claims description 14
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 13
- 230000001954 sterilising effect Effects 0.000 claims description 12
- 102000016938 Catalase Human genes 0.000 claims description 11
- 108010053835 Catalase Proteins 0.000 claims description 11
- 239000007790 solid phase Substances 0.000 claims description 10
- 238000005406 washing Methods 0.000 claims description 10
- 229920001991 Proanthocyanidin Polymers 0.000 claims description 9
- -1 procyanidin compound Chemical class 0.000 claims description 7
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 claims description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 6
- 239000002562 thickening agent Substances 0.000 claims description 6
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 claims description 5
- 239000002202 Polyethylene glycol Substances 0.000 claims description 5
- 229920002125 Sokalan® Polymers 0.000 claims description 5
- 229960001631 carbomer Drugs 0.000 claims description 5
- 235000011187 glycerol Nutrition 0.000 claims description 5
- 229920001223 polyethylene glycol Polymers 0.000 claims description 5
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 claims description 4
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 claims description 4
- 229920002674 hyaluronan Polymers 0.000 claims description 4
- 229960003160 hyaluronic acid Drugs 0.000 claims description 4
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims description 4
- 241001116389 Aloe Species 0.000 claims description 3
- 235000011399 aloe vera Nutrition 0.000 claims description 3
- 239000011259 mixed solution Substances 0.000 claims description 3
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 claims description 2
- NIXOWILDQLNWCW-UHFFFAOYSA-M Acrylate Chemical compound [O-]C(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 claims description 2
- 239000004354 Hydroxyethyl cellulose Substances 0.000 claims description 2
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 claims description 2
- HDSBZMRLPLPFLQ-UHFFFAOYSA-N Propylene glycol alginate Chemical compound OC1C(O)C(OC)OC(C(O)=O)C1OC1C(O)C(O)C(C)C(C(=O)OCC(C)O)O1 HDSBZMRLPLPFLQ-UHFFFAOYSA-N 0.000 claims description 2
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 claims description 2
- 229940071826 hydroxyethyl cellulose Drugs 0.000 claims description 2
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims description 2
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims description 2
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims description 2
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims description 2
- 239000004310 lactic acid Substances 0.000 claims description 2
- 235000014655 lactic acid Nutrition 0.000 claims description 2
- 229920000609 methyl cellulose Polymers 0.000 claims description 2
- 239000001923 methylcellulose Substances 0.000 claims description 2
- 235000010981 methylcellulose Nutrition 0.000 claims description 2
- 229960002900 methylcellulose Drugs 0.000 claims description 2
- 239000000770 propane-1,2-diol alginate Substances 0.000 claims description 2
- 235000010409 propane-1,2-diol alginate Nutrition 0.000 claims description 2
- 239000000230 xanthan gum Substances 0.000 claims description 2
- 235000010493 xanthan gum Nutrition 0.000 claims description 2
- 229920001285 xanthan gum Polymers 0.000 claims description 2
- 229940082509 xanthan gum Drugs 0.000 claims description 2
- JPFCOVZKLAXXOE-XBNSMERZSA-N (3r)-2-(3,5-dihydroxy-4-methoxyphenyl)-8-[(2r,3r,4r)-3,5,7-trihydroxy-2-(4-hydroxyphenyl)-3,4-dihydro-2h-chromen-4-yl]-3,4-dihydro-2h-chromene-3,5,7-triol Chemical compound C1=C(O)C(OC)=C(O)C=C1C1[C@H](O)CC(C(O)=CC(O)=C2[C@H]3C4=C(O)C=C(O)C=C4O[C@@H]([C@@H]3O)C=3C=CC(O)=CC=3)=C2O1 JPFCOVZKLAXXOE-XBNSMERZSA-N 0.000 claims 7
- 230000000694 effects Effects 0.000 abstract description 20
- 230000000844 anti-bacterial effect Effects 0.000 abstract description 9
- 208000002193 Pain Diseases 0.000 abstract description 6
- 239000000126 substance Substances 0.000 abstract description 4
- 206010061218 Inflammation Diseases 0.000 abstract description 3
- 206010020751 Hypersensitivity Diseases 0.000 abstract description 2
- 208000026935 allergic disease Diseases 0.000 abstract description 2
- 230000007815 allergy Effects 0.000 abstract description 2
- 230000008901 benefit Effects 0.000 abstract description 2
- 238000001727 in vivo Methods 0.000 abstract description 2
- 230000004054 inflammatory process Effects 0.000 abstract description 2
- 230000003647 oxidation Effects 0.000 abstract description 2
- 238000007254 oxidation reaction Methods 0.000 abstract description 2
- 230000002411 adverse Effects 0.000 abstract 1
- 230000000052 comparative effect Effects 0.000 description 18
- 239000003814 drug Substances 0.000 description 15
- 210000003491 skin Anatomy 0.000 description 15
- 230000003385 bacteriostatic effect Effects 0.000 description 11
- 239000000306 component Substances 0.000 description 11
- 229940079593 drug Drugs 0.000 description 8
- 150000003254 radicals Chemical class 0.000 description 8
- 238000012360 testing method Methods 0.000 description 8
- 239000003054 catalyst Substances 0.000 description 7
- 239000002674 ointment Substances 0.000 description 7
- 238000006116 polymerization reaction Methods 0.000 description 6
- 208000024891 symptom Diseases 0.000 description 5
- 208000002874 Acne Vulgaris Diseases 0.000 description 4
- 206010000496 acne Diseases 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 229920000642 polymer Polymers 0.000 description 4
- 241000894006 Bacteria Species 0.000 description 3
- 208000010668 atopic eczema Diseases 0.000 description 3
- 230000003796 beauty Effects 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 239000002537 cosmetic Substances 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 229910001385 heavy metal Inorganic materials 0.000 description 3
- 239000005445 natural material Substances 0.000 description 3
- 206010003694 Atrophy Diseases 0.000 description 2
- 208000003251 Pruritus Diseases 0.000 description 2
- 230000002292 Radical scavenging effect Effects 0.000 description 2
- 206010040844 Skin exfoliation Diseases 0.000 description 2
- 206010043189 Telangiectasia Diseases 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 230000037444 atrophy Effects 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 230000003197 catalytic effect Effects 0.000 description 2
- 230000035618 desquamation Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000011010 flushing procedure Methods 0.000 description 2
- 230000007760 free radical scavenging Effects 0.000 description 2
- 150000002500 ions Chemical class 0.000 description 2
- 230000007803 itching Effects 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 229920001542 oligosaccharide Polymers 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000003002 pH adjusting agent Substances 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000002335 preservative effect Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 230000008439 repair process Effects 0.000 description 2
- 230000008591 skin barrier function Effects 0.000 description 2
- 230000008961 swelling Effects 0.000 description 2
- 208000009056 telangiectasis Diseases 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 241000222122 Candida albicans Species 0.000 description 1
- 206010012434 Dermatitis allergic Diseases 0.000 description 1
- 206010013786 Dry skin Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 206010015150 Erythema Diseases 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 241000192125 Firmicutes Species 0.000 description 1
- QQILFGKZUJYXGS-UHFFFAOYSA-N Indigo dye Chemical compound C1=CC=C2C(=O)C(C3=C(C4=CC=CC=C4N3)O)=NC2=C1 QQILFGKZUJYXGS-UHFFFAOYSA-N 0.000 description 1
- 240000007707 Mentha arvensis Species 0.000 description 1
- 235000018978 Mentha arvensis Nutrition 0.000 description 1
- 235000016278 Mentha canadensis Nutrition 0.000 description 1
- 206010067482 No adverse event Diseases 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 206010033733 Papule Diseases 0.000 description 1
- 206010054786 Skin burning sensation Diseases 0.000 description 1
- 208000032140 Sleepiness Diseases 0.000 description 1
- 206010041349 Somnolence Diseases 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- 206010042674 Swelling Diseases 0.000 description 1
- JDLSRXWHEBFHNC-UHFFFAOYSA-N Ufenamate Chemical compound CCCCOC(=O)C1=CC=CC=C1NC1=CC=CC(C(F)(F)F)=C1 JDLSRXWHEBFHNC-UHFFFAOYSA-N 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 235000010208 anthocyanin Nutrition 0.000 description 1
- 229930002877 anthocyanin Natural products 0.000 description 1
- 239000004410 anthocyanin Substances 0.000 description 1
- 150000004636 anthocyanins Chemical class 0.000 description 1
- 230000003266 anti-allergic effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 229910052785 arsenic Inorganic materials 0.000 description 1
- RQNWIZPPADIBDY-UHFFFAOYSA-N arsenic atom Chemical compound [As] RQNWIZPPADIBDY-UHFFFAOYSA-N 0.000 description 1
- 201000008937 atopic dermatitis Diseases 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 229940046731 calcineurin inhibitors Drugs 0.000 description 1
- 229940095731 candida albicans Drugs 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 239000013522 chelant Substances 0.000 description 1
- 239000012295 chemical reaction liquid Substances 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000008358 core component Substances 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000037336 dry skin Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 229940067594 flufenamate Drugs 0.000 description 1
- 229960004369 flufenamic acid Drugs 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- ZFGMDIBRIDKWMY-PASTXAENSA-N heparin Chemical compound CC(O)=N[C@@H]1[C@@H](O)[C@H](O)[C@@H](COS(O)(=O)=O)O[C@@H]1O[C@@H]1[C@@H](C(O)=O)O[C@@H](O[C@H]2[C@@H]([C@@H](OS(O)(=O)=O)[C@@H](O[C@@H]3[C@@H](OC(O)[C@H](OS(O)(=O)=O)[C@H]3O)C(O)=O)O[C@@H]2O)CS(O)(=O)=O)[C@H](O)[C@H]1O ZFGMDIBRIDKWMY-PASTXAENSA-N 0.000 description 1
- 229960001008 heparin sodium Drugs 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 238000005286 illumination Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- QSHDDOUJBYECFT-UHFFFAOYSA-N mercury Chemical compound [Hg] QSHDDOUJBYECFT-UHFFFAOYSA-N 0.000 description 1
- 229910052753 mercury Inorganic materials 0.000 description 1
- 229910021645 metal ion Inorganic materials 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000003020 moisturizing effect Effects 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 230000001151 other effect Effects 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N phenol group Chemical group C1(=CC=CC=C1)O ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- 230000019612 pigmentation Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000009323 psychological health Effects 0.000 description 1
- 201000004700 rosacea Diseases 0.000 description 1
- 230000037307 sensitive skin Effects 0.000 description 1
- 230000037321 sleepiness Effects 0.000 description 1
- 230000003637 steroidlike Effects 0.000 description 1
- 210000000434 stratum corneum Anatomy 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 125000000647 trehalose group Chemical group 0.000 description 1
- 229950010121 ufenamate Drugs 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 230000002087 whitening effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
- A61K8/4973—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom
- A61K8/498—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom having 6-membered rings or their condensed derivatives, e.g. coumarin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/34—Alcohols
- A61K8/345—Alcohols containing more than one hydroxy group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/67—Vitamins
- A61K8/678—Tocopherol, i.e. vitamin E
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/73—Polysaccharides
- A61K8/733—Alginic acid; Salts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/73—Polysaccharides
- A61K8/736—Chitin; Chitosan; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/81—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds obtained by reactions involving only carbon-to-carbon unsaturated bonds
- A61K8/8141—Compositions of homopolymers or copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by only one carboxyl radical, or of salts, anhydrides, esters, amides, imides or nitriles thereof; Compositions of derivatives of such polymers
- A61K8/8147—Homopolymers or copolymers of acids; Metal or ammonium salts thereof, e.g. crotonic acid, (meth)acrylic acid; Compositions of derivatives of such polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/84—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds obtained by reactions otherwise than those involving only carbon-carbon unsaturated bonds
- A61K8/86—Polyethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/92—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof
- A61K8/922—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof of vegetable origin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9794—Liliopsida [monocotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
- A61Q17/005—Antimicrobial preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/52—Stabilizers
- A61K2800/522—Antioxidants; Radical scavengers
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Birds (AREA)
- Dermatology (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention discloses a facial hormone-dependent dermatitis treatment liquid based on procyanidine oligomers and a preparation method thereof. The facial hormone-dependent dermatitis treatment liquid is mainly prepared by mixing a humectant, a viscous agent, deionized water, biological polypeptide, a pH regulator, a procyanidine composite liquid and vitamin E; the biological polypeptide is a mixture of tridecapeptide and glutathione, and the procyanidin complex liquid is prepared by reacting procyanidin oligomer, trehalose, chitosan, aloe extract and peppermint oil. Procyanidin oligomer is a natural chemical substance, has the characteristics of resisting inflammation, resisting allergy, eliminating in-vivo free radicals, resisting oxidation and the like, and chitosan has an excellent antibacterial function; combining procyanidin oligomer with chitosan, and adding oleum Menthae Dementholatum to reduce burning and pain; finally preparing the facial hormone-dependent dermatitis treatment liquid; the therapeutic liquid has the advantages of simple application method, no adverse side effects, and good therapeutic effect.
Description
Technical Field
The invention relates to the technical field of cosmetics, in particular to a facial hormone-dependent dermatitis treatment liquid based on procyanidine oligomers and a preparation method thereof.
Background
The facial hormone-dependent dermatitis is a common dermatological disease, and clinical symptoms are mostly manifested by thinning of stratum corneum, atrophy, flushing, telangiectasia, acne, rosacea and the like, and are accompanied by a little of thin crumbs, pigmentation, dryness, itching and burning touch. The causes of facial hormone-dependent dermatitis are roughly the following: 1. the medicine is improperly selected, and the patient can select the medicine containing the hormone by himself without the guidance of a doctor; 2. the medicine is not properly taken, the administration time is too long, and the skin barrier function can be damaged by long-term use of hormone medicines, so that the hormone medicines generate dependence on the medicines, and malignant circulation is caused; 3. in order to meet the expectation of beauty of patients, a beauty institution uses a large amount of hormone medicines, and can show the effects of whitening and beautifying in a short time; but the long-term use of the medicine can form dependence to cause the disease. The treatment period of the facial hormone-dependent dermatitis is long, the disease condition is easy to repeat, the facial beauty is affected, and the physical and psychological health of a patient is harmed.
The traditional Chinese medicine considers that hormone medicines are externally used for a long time and accumulated on skin, and can help yang to transform heat, heat injure blood collaterals, consume body fluid and injure yin; the external application of indigo naturalis ointment, cortex Phellodendri ointment and radix Angelicae sinensis ointment is mostly adopted in treatment, the effect is not obvious, and the repeated application is easy. The western medicine for treating the facial hormone-dependent dermatitis mostly adopts medicines such as calcineurin inhibitors, non-steroidal medicines, heparin sodium ointment and the like for local treatment, and the treatment method has certain treatment effect, but can bring sleepiness, and can bring burning pain, dryness and desquamation discomfort when being externally used. Therefore, it is of value to study a pharmaceutical preparation which is effective in treating facial hormone-dependent dermatitis, safe and harmless, and has little side effects.
At present, the procyanidin-containing external treatment liquid for treating the facial hormone-dependent dermatitis is less, but the invention provides the external treatment liquid for the facial hormone-dependent dermatitis, which takes procyanidin oligomers as main raw materials, and the external treatment liquid has the advantages of simple use method, excellent treatment effect and no toxic or side effect; has been successfully applied to clinical treatment by various hospitals and has achieved good treatment effect.
Disclosure of Invention
The invention aims to provide a facial hormone-dependent dermatitis treatment liquid based on procyanidine oligomers and a preparation method thereof, so as to solve the problems in the background technology.
In order to solve the technical problems, the invention provides the following technical scheme: a facial hormone-dependent dermatitis therapeutic liquid based on procyanidin oligomer comprises humectant 1.0-5.0%, viscous agent 0.1-0.3%, biological polypeptide 13-17%, pH regulator 0.05-0.35%, procyanidin complex liquid 1.5-2.5%, vitamin E0.06-0.12%, and deionized water in balance.
Further, the procyanidin compound liquid is mainly prepared by reacting procyanidin oligomer, trehalose, chitosan, aloe extract and peppermint oil, wherein the addition amount of the peppermint oil is 0.01% of the total amount.
Further, the biological polypeptide is a mixture of tridecapeptide and glutathione; the mass ratio of the tridecapeptide to the glutathione is 2: 1; according to the scheme, the tridecapeptide and the glutathione are added to promote the healing of the acne and repair the skin barrier; the skin care product can provide amino acids and other nutrients to the skin during treatment, and promote the skin to quickly recover to a healthy state.
Further, the humectant is any one of propylene glycol, polyethylene glycol, glycerin and hyaluronic acid, preferably, the humectant is a mixed solution of hyaluronic acid, glycerin and polyethylene glycol.
Further, the thickening agent is any one or more of carbomer, xanthan gum, hydroxyethyl cellulose, methyl cellulose, hydroxypropyl methyl cellulose, propylene glycol alginate and acrylate, and preferably the thickening agent is carbomer.
Further, the pH adjusting agent is any one of citric acid, potassium hydroxide, lactic acid, and triethanolamine, and preferably, the pH adjusting agent is triethanolamine.
Further, the facial hormone-dependent dermatitis treatment liquid based on the procyanidine oligomer comprises the following raw material components:
a method for preparing facial hormone-dependent dermatitis therapeutic solution based on procyanidin oligomer comprises: comprises the following steps of (a) carrying out,
(1) dissolving procyanidine oligomer in ethanol solution, and adding lipase to obtain solution A; dissolving chitosan in an ethanol solution, dropwise adding a sodium hydroxide solution, adding a hydrogen peroxide solution, wherein the mass ratio of the hydrogen peroxide solution to lipase is 5:1, stirring, reacting, heating, dropwise adding the solution A, standing for reacting after dropwise adding, separating to obtain a solid phase, washing with absolute ethanol, adding trehalose and deionized water, and stirring at a high speed to obtain a solution B; heating the aloe extract, adding the solution B, dispersing at high speed, cooling to room temperature, dropwise adding peppermint oil, and stirring to obtain procyanidin composite liquid;
(2) mixing deionized water, thickening agent and humectant, stirring, and homogenizing in homogenizer; adding biological polypeptide, procyanidin complex solution, and vitamin E, stirring at high speed, adding pH regulator dropwise, stirring, and naturally cooling to room temperature; sterilizing to obtain the finished product of the facial hormone-dependent dermatitis treatment liquid based on the procyanidine oligomer.
Further, a preparation method of the facial hormone-dependent dermatitis treatment liquid based on procyanidine oligomers comprises the following steps;
(1) dissolving procyanidin oligomer in ethanol solution, adding lipase and trehalose, wherein the addition amount of trehalose is 50% of that of procyanidin oligomer, adding trehalose in two times, and adding 1/10 trehalose. Stirring for 8-10min to obtain solution A; dissolving chitosan in ethanol solution, dropwise adding sodium hydroxide solution until pH is 8.0-10.0, adding hydrogen peroxide solution, stirring, reacting for 10-20min, heating to 42-47 deg.C, dropwise adding solution A, and standing for 40-60 min; adding catalase, stirring, separating to obtain a solid phase, washing with absolute ethanol, adding the residual 9/10 trehalose and deionized water, and stirring at a high speed of 800 r/min; obtaining a solution B; heating Aloe extractive solution to 55-60 deg.C, adding solution B, dispersing at high speed, cooling to room temperature, adding oleum Menthae Dementholatum dropwise, stirring for 8-10min to obtain procyanidin complex solution;
the procyanidin oligomer is a natural substance extracted from plants, has excellent inoxidizability, in-vivo free radical scavenging, anti-inflammatory, antibacterial and other effects, but has very active property and is unstable under the conditions of illumination, temperature, metal ions and the like due to the fact that the procyanidin oligomer contains a plurality of phenolic hydroxyl groups, so that the application efficiency of the procyanidin oligomer is reduced; the chitosan is also a natural substance, has natural antibacterial and bacteriostatic effects, has an inhibiting effect on gram-positive bacteria, gram-negative bacteria, candida albicans and other strains, can capture heavy metal ions such as lead, mercury and arsenic to form a chelate with the heavy metal ions, and avoids the pollution of the heavy metal to the skin; but the bacteriostatic effect is not obvious when the chitosan is used alone. The technical scheme effectively combines the procyanidine oligomer and the chitosan, improves respective defects and enables the two substances to exert the maximum effect. Under the action of a catalyst, procyanidin oligomer and chitosan are subjected to polymerization reaction and are connected by covalent bonds to form a polymer. The catalyst is hydrogen peroxide and lipase with the mass ratio of 5:1, the combination of the hydrogen peroxide and the lipase has higher catalytic efficiency than the single use of the hydrogen peroxide, and the polymerization of procyanidine oligomer and chitosan is promoted more quickly and thoroughly; when lipase is added, a small amount of trehalose is used in a matching manner, and the trehalose serving as a natural preservative can be used as a stable medium of the lipase, so that the activity and stability of the lipase can be improved, and the catalytic effect is ensured. After the polymerization reaction is finished, the hydrogen peroxide is remained in the reaction liquid; because the hydrogen peroxide has oxidability, the skin can be burnt when the skin is wiped on a wound, and the skin can be burnt by serious people; therefore, according to the technical scheme, catalase is added after the polymerization reaction is finished, and the catalase is decomposed to avoid skin burning sensation and other injuries brought by the catalase. The polymer formed by procyanidin oligomer and chitosan has the characteristics of two compounds, has excellent oxidation resistance, free radical removal, anti-inflammation, anti-allergy, antibacterial and bacteriostatic effects, and can be used for treating and preventing symptoms such as cuticle thinning, atrophy, flushing, telangiectasia, acne and the like when being applied to an affected part of hormone-dependent dermatitis. Trehalose is a natural saccharide and has a magical protective effect on organisms; after procyanidine oligomer and chitosan form a polymer, adding trehalose, wherein the trehalose structure has an oxygen six-membered ring, and hydroxyl methoxyl groups on the oxygen six-membered ring can perform saccharification reaction with anthocyanin in procyanidine to form a stable complex; thereby further improving the stability of the polymer and ensuring the treatment effect of the treatment solution.
Natural substances extracted from fresh stems and leaves of Mentha arvensis can be used for skin or mucosa to produce cooling feeling to relieve discomfort and pain. The scheme adds a trace amount of peppermint oil, and can reduce burning and pain of sensitive skin in the treatment process while not influencing the treatment effect.
The vitamin E, the carbomer, the glycerol and the polyethylene glycol have good mixing effect with the skin, and a layer of wet repairing film can be formed on the surface of the skin; the skin care product can isolate foreign substances from invading the skin, lock skin moisture, prevent evaporation, and improve the phenomena of dry skin and desquamation of patients.
(2) Mixing deionized water, viscous agent and humectant, stirring at 300-500r/min for 5-6min, and homogenizing in homogenizer for 8-15 min; adding biological polypeptide, procyanidin complex solution, and vitamin E, stirring at high speed of 500r/min and 65-70 deg.C for 5-6min, dropwise adding pH regulator, stirring for 20-30min, and naturally cooling to room temperature; sterilizing to obtain the finished product of the facial hormone-dependent dermatitis treatment liquid based on the procyanidine oligomer.
Compared with the prior art, the invention has the following beneficial effects: the core component procyanidin mixed solution of the treatment solution is obtained by reacting procyanidin oligomer, trehalose, chitosan, aloe extract and peppermint oil, has excellent functions of eliminating free radicals, resisting inflammation, allergy, bacteria and bacteria, and can relieve edema, protect capillary vessels, inhibit the activity of inflammatory factors and improve allergic symptoms; adding trace amount of oleum Menthae Dementholatum to relieve burning and pain during application; furthermore, biological polypeptide and vitamin E further repair the skin to form a moisturizing and water-locking layer. Raw materials selected from procyanidine oligomer, trehalose, chitosan, aloe extract and peppermint oil in the treatment liquid belong to natural pollution-free substances, and no preservative component is added, so that the product is high in safety and simple in use method; there have been many successful clinical treatment cases.
Detailed Description
The technical solutions in the embodiments of the present invention are clearly and completely described below, and it is obvious that the described embodiments are only a part of the embodiments of the present invention, and not all embodiments. All other embodiments, which can be derived by a person skilled in the art from the embodiments given herein without making any creative effort, shall fall within the protection scope of the present invention.
Example 1
A facial hormone-dependent dermatitis treatment liquid based on procyanidine oligomers comprises the following raw material components:
a method for preparing facial hormone-dependent dermatitis therapeutic solution based on procyanidin oligomer comprises the following steps,
(1) dissolving procyanidin oligomer in ethanol solution, adding lipase and trehalose, and stirring for 8min to obtain solution A; dissolving chitosan in ethanol solution, dropwise adding sodium hydroxide solution until the pH value is 8.0, adding hydrogen peroxide solution, stirring, reacting for 10min, raising the temperature to 42 ℃, dropwise adding the solution A, and standing and reacting for 40min after dropwise adding; adding catalase, stirring, separating to obtain a solid phase, washing with absolute ethanol, adding trehalose and deionized water, and stirring at a high speed of 500 r/min; obtaining a solution B; heating Aloe extractive solution to 55 deg.C, adding solution B, dispersing at high speed, cooling to room temperature, adding oleum Menthae Dementholatum dropwise, stirring for 8min to obtain procyanidin complex solution;
(2) mixing deionized water, viscous agent and humectant, stirring at 300r/min for 5min, and homogenizing in homogenizer for 8 min; adding biological polypeptide, procyanidin complex solution, and vitamin E, stirring at high speed for 5min at a stirring speed of 300r/min and a temperature of 65 deg.C, dropwise adding pH regulator, stirring for 20min, and naturally cooling to room temperature; sterilizing to obtain the finished product of the facial hormone-dependent dermatitis treatment liquid based on the procyanidine oligomer.
Example 2
A facial hormone-dependent dermatitis treatment liquid based on procyanidine oligomers comprises the following raw material components:
a method for preparing facial hormone-dependent dermatitis therapeutic solution based on procyanidin oligomer comprises the following steps,
(1) dissolving procyanidin oligomer in ethanol solution, adding lipase and trehalose, and stirring for 9min to obtain solution A; dissolving chitosan in ethanol solution, dropwise adding sodium hydroxide solution until the pH value is 8.5, adding hydrogen peroxide solution, stirring, reacting for 15min, raising the temperature to 45 ℃, dropwise adding the solution A, and standing and reacting for 45min after dropwise adding; adding catalase, stirring, separating to obtain a solid phase, washing with absolute ethanol, adding trehalose and deionized water, and stirring at a high speed of 630 r/min; obtaining a solution B; heating the aloe extract to 57 ℃, adding the solution B, dispersing at a high speed, cooling to room temperature, dropwise adding peppermint oil, and stirring for 9min to obtain procyanidin composite liquid;
(2) mixing deionized water, viscous agent and humectant, stirring at 400r/min for 5.5min, and homogenizing in homogenizer for 10 min; adding biological polypeptide, procyanidin complex solution, and vitamin E, stirring at high speed for 5min at 67 deg.C under 420r/min, adding dropwise pH regulator, stirring for 25min, and naturally cooling to room temperature; sterilizing to obtain the finished product of the facial hormone-dependent dermatitis treatment liquid based on the procyanidine oligomer.
Example 3
A facial hormone-dependent dermatitis treatment liquid based on procyanidine oligomers comprises the following raw material components:
a method for preparing facial hormone-dependent dermatitis therapeutic solution based on procyanidin oligomer comprises the following steps,
(1) dissolving procyanidin oligomer in ethanol solution, adding lipase and trehalose, and stirring for 10min to obtain solution A; dissolving chitosan in an ethanol solution, dropwise adding a sodium hydroxide solution until the pH value is 10.0, adding a hydrogen peroxide solution, stirring, reacting for 20min, raising the temperature to 47 ℃, dropwise adding the solution A, standing and reacting for 60min after dropwise adding, adding catalase, stirring, separating to obtain a solid phase, washing with absolute ethanol, adding trehalose and deionized water, and stirring at a high speed, wherein the stirring speed is 800 r/min; obtaining a solution B; heating the aloe extract to 60 ℃, adding the solution B, dispersing at a high speed, cooling to room temperature, dropwise adding peppermint oil, and stirring for 10min to obtain procyanidin composite liquid;
(2) mixing deionized water, viscous agent and humectant, stirring at 500r/min for 5-6min, and homogenizing in homogenizer for 15 min; adding biological polypeptide, procyanidin complex solution, and vitamin E, stirring at high speed for 5-6min at 70 deg.C and 500r/min, adding dropwise pH regulator, stirring for 30min, and naturally cooling to room temperature; sterilizing to obtain the finished product of the facial hormone-dependent dermatitis treatment liquid based on the procyanidine oligomer.
Comparative example 1
A facial hormone-dependent dermatitis treatment liquid based on procyanidine oligomers comprises the following raw material components:
a method for preparing facial hormone-dependent dermatitis therapeutic solution based on procyanidin oligomer comprises the following steps,
(1) dissolving procyanidin oligomer in ethanol solution, adding lipase, and stirring for 10min to obtain solution A; dissolving chitosan in an ethanol solution, dropwise adding a sodium hydroxide solution until the pH value is 10.0, adding a hydrogen peroxide solution, stirring, reacting for 20min, raising the temperature to 47 ℃, dropwise adding the solution A, standing and reacting for 60min after dropwise adding, adding catalase, stirring, separating to obtain a solid phase, washing with absolute ethanol, adding trehalose and deionized water, and stirring at a high speed, wherein the stirring speed is 800 r/min; obtaining a solution B; heating the aloe extract to 60 ℃, adding the solution B, dispersing at a high speed, cooling to room temperature, dropwise adding peppermint oil, and stirring for 10min to obtain procyanidin composite liquid;
(2) mixing deionized water, viscous agent and humectant, stirring at 500r/min for 5-6min, and homogenizing in homogenizer for 15 min; adding biological polypeptide, procyanidin complex solution, and vitamin E, stirring at high speed for 5-6min at 70 deg.C and 500r/min, adding dropwise pH regulator, stirring for 30min, and naturally cooling to room temperature; sterilizing to obtain the finished product of the facial hormone-dependent dermatitis treatment liquid based on the procyanidine oligomer.
Comparative example 2
A facial hormone-dependent dermatitis treatment liquid based on procyanidine oligomers comprises the following raw material components:
a method for preparing facial hormone-dependent dermatitis therapeutic solution based on procyanidin oligomer comprises the following steps,
(1) dissolving procyanidin oligomer in ethanol solution, and stirring for 10min to obtain solution A; dissolving chitosan in an ethanol solution, dropwise adding a sodium hydroxide solution until the pH value is 10.0, stirring, reacting for 20min, raising the temperature to 47 ℃, dropwise adding the solution A, standing for reacting for 60min after dropwise adding, adding catalase, stirring, separating to obtain a solid phase, washing with absolute ethanol, adding trehalose and deionized water, and stirring at a high speed at the stirring speed of 800 r/min; obtaining a solution B; heating the aloe extract to 60 ℃, adding the solution B, dispersing at a high speed, cooling to room temperature, dropwise adding peppermint oil, and stirring for 10min to obtain procyanidin composite liquid;
(2) mixing deionized water, viscous agent and humectant, stirring at 500r/min for 5-6min, and homogenizing in homogenizer for 15 min; adding biological polypeptide, procyanidin complex solution, and vitamin E, stirring at high speed for 5-6min at 70 deg.C and 500r/min, adding dropwise pH regulator, stirring for 30min, and naturally cooling to room temperature; sterilizing to obtain the finished product of the facial hormone-dependent dermatitis treatment liquid based on the procyanidine oligomer.
Comparative example 3
A facial hormone-dependent dermatitis treatment liquid based on procyanidine oligomers comprises the following raw material components:
a method for preparing facial hormone-dependent dermatitis therapeutic solution based on procyanidin oligomer comprises the following steps,
(1) dissolving procyanidin oligomer in ethanol solution, adding lipase, and stirring for 10min to obtain solution A; the chitosan was dissolved in the ethanol solution, and sodium hydroxide solution was added dropwise to a pH of 10.0, and the reaction was not allowed to proceed with stirring, and this experiment was terminated.
Comparative example 4
A facial hormone-dependent dermatitis treatment liquid based on procyanidine oligomers comprises the following raw material components:
a method for preparing facial hormone-dependent dermatitis therapeutic solution based on procyanidin oligomer comprises the following steps,
(1) dissolving procyanidin oligomer in ethanol solution, and stirring for 10min to obtain solution A; dissolving chitosan in an ethanol solution, dropwise adding a sodium hydroxide solution until the pH value is 10.0, adding a hydrogen peroxide solution, stirring, reacting for 20min, raising the temperature to 47 ℃, dropwise adding the solution A, standing and reacting for 60min after dropwise adding, adding catalase, stirring, separating to obtain a solid phase, washing with absolute ethanol, adding deionized water, and stirring at a high speed, wherein the stirring speed is 800 r/min; obtaining a solution B; heating the aloe extract to 60 ℃, adding the solution B, dispersing at a high speed, cooling to room temperature, dropwise adding peppermint oil, and stirring for 10min to obtain procyanidin composite liquid;
(2) mixing deionized water, viscous agent and humectant, stirring at 500r/min for 5-6min, and homogenizing in homogenizer for 15 min; adding biological polypeptide, procyanidin complex solution, and vitamin E, stirring at high speed for 5-6min at 70 deg.C and 500r/min, adding dropwise pH regulator, stirring for 30min, and naturally cooling to room temperature; sterilizing to obtain the finished product of the facial hormone-dependent dermatitis treatment liquid based on the procyanidine oligomer.
Comparative example 5
A facial hormone-dependent dermatitis treatment liquid based on procyanidine oligomers comprises the following raw material components:
a method for preparing facial hormone-dependent dermatitis therapeutic solution based on procyanidin oligomer comprises the following steps,
(1) mixing procyanidin oligomer, trehalose, deionized water, and Aloe extract, dispersing at high speed, cooling to room temperature, adding oleum Menthae Dementholatum dropwise, stirring for 10min to obtain procyanidin complex solution;
(2) mixing deionized water, viscous agent and humectant, stirring at 500r/min for 5-6min, and homogenizing in homogenizer for 15 min; adding biological polypeptide, procyanidin complex solution, and vitamin E, stirring at high speed for 5-6min at 70 deg.C and 500r/min, adding dropwise pH regulator, stirring for 30min, and naturally cooling to room temperature; sterilizing to obtain the finished product of the facial hormone-dependent dermatitis treatment liquid based on the procyanidine oligomer.
Comparative example 6
A facial hormone-dependent dermatitis treatment liquid based on procyanidine oligomers comprises the following raw material components:
a method for preparing facial hormone-dependent dermatitis therapeutic solution based on procyanidin oligomer comprises the following steps,
(1) mixing procyanidin oligomer, deionized water and Aloe extract, dispersing at high speed, cooling to room temperature, adding oleum Menthae Dementholatum dropwise, stirring for 10min to obtain procyanidin compound solution;
(2) mixing deionized water, viscous agent and humectant, stirring at 500r/min for 5-6min, and homogenizing in homogenizer for 15 min; adding biological polypeptide, procyanidin complex solution, and vitamin E, stirring at high speed for 5-6min at 70 deg.C and 500r/min, adding dropwise pH regulator, stirring for 30min, and naturally cooling to room temperature; sterilizing to obtain the finished product of the facial hormone-dependent dermatitis treatment liquid based on the procyanidine oligomer.
Experimental comparison and analysis
Examples 1-3 are the present technical solution,
in the comparative example 1, the catalyst in the procyanidin complex liquid is lipase + hydrogen peroxide, the lipase is not used in combination with trehalose, and the rest contents are the same as those in the example 3;
in the comparison example 2, the catalyst in the procyanidin composite liquid only uses hydrogen peroxide, and the rest is the same as that in the example 3;
in the comparative example 3, the catalyst in the procyanidine composite liquid is only lipase, and the rest contents are the same as those in the example 3;
in the comparative example 4, the chitosan in the procyanidine composite liquid is only added once and is matched with lipase for use, and is not added later; the rest is the same as in example 3;
in the comparative example 5, chitosan is not added into the procyanidine composite liquid, and the rest contents are the same as those in the example 3;
in the comparative example 6, chitosan and trehalose are not added into the procyanidin composite liquid, and the rest contents are the same as those in the example 3;
the antibacterial and bacteriostatic performance and the free radical clearance of the finished treatment solutions prepared in the examples 1-3 and the comparative examples 1-6 are detected; the antibacterial and bacteriostatic performance detection takes staphylococcus aureus and escherichia coli as representatives.
Detecting the antibacterial performance by adopting an antibacterial zone automatic determinator, and determining the radical clearance by adopting an ABTS (anaerobic-baffled transfer System) radical clearance method; the detection data are shown in table 1;
TABLE 1
As can be seen from table 1, the treatments prepared in examples 1-3 were excellent in both bacteriostatic activity and free radical scavenging rate, with example 2 being the best option. In comparative example 1, the polymerization degree of lipase was slightly decreased without trehalose protection, so that the bacteriostatic effect and the radical scavenging rate were slightly lower than those of the examples. In comparative example 2, the catalyst used only hydrogen peroxide, which is less effective than the combination of hydrogen peroxide and lipase, and the degree of polymerization is low, so that the bacteriostatic effect and the radical scavenging rate are greatly different from those of the examples. In comparative example 3, the catalyst only used lipase, and it was analyzed that the decomposition rate of procyanidin by lipase was extremely low, which resulted in failure of the reaction and termination of the test. In comparative example 4, trehalose was used only once, in combination with lipase action; the stability of the proanthocyanidin oligosaccharide is not improved by combination with the proanthocyanidin oligosaccharide, so that the bacteriostatic effect and the free radical clearance rate are relatively weak. In the comparative example 5, because chitosan is not added, the bacteriostatic effect is obviously reduced, and in the comparative example 6, chitosan and trehalose are not added, the bacteriostatic performance and the free radical clearance rate are the weakest; therefore, the technical scheme is a relatively optimized scheme and has excellent antibacterial performance and free radical clearance.
EXAMPLE 4 clinical treatment trial
The therapeutic solution prepared in example 2 was selected for clinical treatment trials
Searching 60 patients with facial hormone-dependent dermatitis; the specific case is described as follows: 30 cases in men and 30 cases in women; the age is from 19 to 45 years; the patient has used one or more of sanjiu dermatitis treating medicine, Allolosong, Parreferring, hormone-containing cosmetics, etc. with a use period of 3-2 years, and an average use period of 7 months. 42 cases of allergic dermatitis, 9 cases of facial acne, 7 cases of thin red blood filaments of facial cuticle and 2 cases of facial dermatitis eczema; the medical history is from 6 months to 3 years, and the average medical history is 13 months; patients 60 were randomly divided into 2 groups, 30 in the test group and 30 in the control group.
The test treatment method comprises the following steps: 60 patients stop using the above drugs or hormone cosmetics for 7 days.
A test group, wherein the affected part is coated with the therapeutic liquid prepared in the embodiment 2, the coating amount is 2ml each time, and the affected part is coated once in the morning and at night each day; in the control group, the flufenamic acid butyl ester ointment is applied to the affected part, the dosage is 2ml each time, and the flufenamic acid butyl ointment is applied once in the morning and at night each day; after the patients of the test group and the control group are continuously used for 60 days, the treatment effect is verified and evaluated.
Evaluation of therapeutic effect: evaluating the degree of relief of symptoms such as itching, redness, swelling, papules, blisters, exudation, burning, swelling, pain, etc. after treatment; evaluation criteria: the treatment effect is divided into complete cure, obvious relief, slight relief and ineffectiveness; the evaluation results are shown in Table 2;
| group of | The number of participating persons | Can completely cure the disease | Significant relief | Mild relief | Invalidation |
| Test group | 30 | 27 | 3 | 0 | 0 |
| Control group | 30 | 8 | 14 | 8 | 0 |
TABLE 2
As can be seen from the data in Table 2, after 30 patients in the test group are treated by the treatment solution, 27 patients are completely cured, 3 patients have obviously relieved skin inflammation, and 0 patient has no effect; after the control group adopts the flufenamate butyl ointment for treatment, 8 patients are cured, 14 patients have obvious symptoms and 8 patients have slight relief; therefore, the treatment liquid prepared by the invention has better treatment effect and no toxic or side effect, and no adverse event or side effect is found in the clinical test process.
Finally, it should be noted that: although the present invention has been described in detail with reference to the foregoing embodiments, it will be apparent to those skilled in the art that changes may be made in the embodiments and/or equivalents thereof without departing from the spirit and scope of the invention. Any modification, equivalent replacement, or improvement made within the spirit and principle of the present invention should be included in the protection scope of the present invention.
Claims (9)
1. A facial hormone-dependent dermatitis therapeutic solution based on procyanidin oligomers is characterized in that; the raw material components comprise 1.0-5.0% of humectant, 0.1-0.3% of viscous agent, 13-17% of biological polypeptide, 0.05-0.35% of pH regulator, 1.5-2.5% of procyanidine complex liquid, 0.06-0.12% of vitamin E and the balance of deionized water.
2. The proanthocyanidin oligomer-based therapeutic solution for facial hormone-dependent dermatitis as claimed in claim 1, wherein: the procyanidin compound liquid is prepared from procyanidin oligomer, trehalose, chitosan, aloe extract and oleum Menthae Dementholatum by reacting.
3. The proanthocyanidin oligomer-based therapeutic solution for facial hormone-dependent dermatitis as claimed in claim 1, wherein: the biological polypeptide is a mixture of tridecapeptide and glutathione.
4. The proanthocyanidin oligomer-based therapeutic solution for facial hormone-dependent dermatitis as claimed in claim 1, wherein: the humectant is any one of propylene glycol, polyethylene glycol, glycerol and hyaluronic acid, and preferably, the humectant is a mixed solution of hyaluronic acid, glycerol and polyethylene glycol.
5. The proanthocyanidin oligomer-based therapeutic solution for facial hormone-dependent dermatitis as claimed in claim 1, wherein: the thickening agent is any one or more of carbomer, xanthan gum, hydroxyethyl cellulose, methyl cellulose, hydroxypropyl methyl cellulose, propylene glycol alginate and acrylate, and preferably the thickening agent is carbomer.
6. The proanthocyanidin oligomer-based therapeutic solution for facial hormone-dependent dermatitis as claimed in claim 1, wherein: the pH regulator is any one of citric acid, potassium hydroxide, lactic acid and triethanolamine, and preferably the pH regulator is triethanolamine.
7. The proanthocyanidin oligomer-based therapeutic solution for facial hormone-dependent dermatitis as claimed in claim 1, wherein: preferably, the raw material components are as follows:
8. a preparation method of facial hormone-dependent dermatitis treatment liquid based on procyanidine oligomers is characterized by comprising the following steps: comprises the following steps of (a) carrying out,
(1) dissolving procyanidine oligomer in ethanol solution, and adding lipase to obtain solution A; dissolving chitosan in an ethanol solution, dropwise adding a sodium hydroxide solution, adding a hydrogen peroxide solution, stirring, reacting, heating, dropwise adding the solution A, standing for reacting after dropwise adding is finished, separating to obtain a solid phase, washing with absolute ethanol, adding trehalose and deionized water, and stirring at a high speed to obtain a solution B; heating the aloe extract, adding the solution B, dispersing at high speed, cooling to room temperature, dropwise adding peppermint oil, and stirring to obtain procyanidin composite liquid;
(2) mixing deionized water, thickening agent and humectant, stirring, and homogenizing in homogenizer; adding biological polypeptide, procyanidin complex solution, and vitamin E, stirring at high speed, adding pH regulator dropwise, stirring, and naturally cooling to room temperature; sterilizing to obtain the finished product of the facial hormone-dependent dermatitis treatment liquid based on the procyanidine oligomer.
9. The method of preparing a proanthocyanidin oligomer-based therapeutic solution for facial hormone-dependent dermatitis as claimed in claim 8, wherein: comprises the following steps of (a) carrying out,
(1) dissolving procyanidin oligomer in ethanol solution, adding lipase and trehalose, and stirring for 8-10min to obtain solution A; dissolving chitosan in ethanol solution, dropwise adding sodium hydroxide solution until pH is 8.0-10.0, adding hydrogen peroxide solution, stirring, reacting for 10-20min, heating to 42-47 deg.C, dropwise adding solution A, and standing for 40-60 min; adding catalase, stirring, separating to obtain a solid phase, washing with absolute ethanol, adding trehalose and deionized water, and stirring at a high speed of 800 r/min; obtaining a solution B; heating Aloe extractive solution to 55-60 deg.C, adding solution B, dispersing at high speed, cooling to room temperature, adding oleum Menthae Dementholatum dropwise, stirring for 8-10min to obtain procyanidin complex solution;
(2) mixing deionized water, viscous agent and humectant, stirring at 300-500r/min for 5-6min, and homogenizing in homogenizer for 8-15 min; adding biological polypeptide, procyanidin complex solution, and vitamin E, stirring at high speed of 500r/min and 65-70 deg.C for 5-6min, dropwise adding pH regulator, stirring for 20-30min, and naturally cooling to room temperature; sterilizing to obtain the finished product of the facial hormone-dependent dermatitis treatment liquid based on the procyanidine oligomer.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010827872.0A CN111840115A (en) | 2020-08-17 | 2020-08-17 | Procyanidine oligomer-based facial hormone-dependent dermatitis treatment liquid and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010827872.0A CN111840115A (en) | 2020-08-17 | 2020-08-17 | Procyanidine oligomer-based facial hormone-dependent dermatitis treatment liquid and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN111840115A true CN111840115A (en) | 2020-10-30 |
Family
ID=72969075
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202010827872.0A Pending CN111840115A (en) | 2020-08-17 | 2020-08-17 | Procyanidine oligomer-based facial hormone-dependent dermatitis treatment liquid and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN111840115A (en) |
Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1486700A (en) * | 2002-09-30 | 2004-04-07 | 王洪栋 | Proanthocyanidin compound and its prepn |
| CH694629A5 (en) * | 2000-12-22 | 2005-05-13 | Mibelle Ag Cosmetics | Hair treatment agent |
| DE102007028397A1 (en) * | 2007-06-15 | 2008-12-18 | Gerhard Knapp | Cosmetic agent, useful e.g. to reduce hair loss and to promote hair growth, comprises phase transfer catalyst made from brown algae, oligomeric procyanidine, humulone and a combination product of catalyst, procyanidine and humulone |
| CN102964468A (en) * | 2012-11-22 | 2013-03-13 | 石家庄亿生堂医用品有限公司 | Procyanidine-modified carboxymethyl chitosan |
| CN106852726A (en) * | 2017-01-17 | 2017-06-16 | 上海应用技术大学 | A kind of OPC microcapsules and preparation method thereof |
| CN107602725A (en) * | 2017-10-16 | 2018-01-19 | 河北工业大学 | A kind of chitosan OPC graft copolymer and application |
| CN110423789A (en) * | 2019-08-15 | 2019-11-08 | 青岛科技大学 | A kind of graft copolymer, the preparation method and application of chitosan and procyanidine |
-
2020
- 2020-08-17 CN CN202010827872.0A patent/CN111840115A/en active Pending
Patent Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CH694629A5 (en) * | 2000-12-22 | 2005-05-13 | Mibelle Ag Cosmetics | Hair treatment agent |
| CN1486700A (en) * | 2002-09-30 | 2004-04-07 | 王洪栋 | Proanthocyanidin compound and its prepn |
| DE102007028397A1 (en) * | 2007-06-15 | 2008-12-18 | Gerhard Knapp | Cosmetic agent, useful e.g. to reduce hair loss and to promote hair growth, comprises phase transfer catalyst made from brown algae, oligomeric procyanidine, humulone and a combination product of catalyst, procyanidine and humulone |
| CN102964468A (en) * | 2012-11-22 | 2013-03-13 | 石家庄亿生堂医用品有限公司 | Procyanidine-modified carboxymethyl chitosan |
| CN106852726A (en) * | 2017-01-17 | 2017-06-16 | 上海应用技术大学 | A kind of OPC microcapsules and preparation method thereof |
| CN107602725A (en) * | 2017-10-16 | 2018-01-19 | 河北工业大学 | A kind of chitosan OPC graft copolymer and application |
| CN110423789A (en) * | 2019-08-15 | 2019-11-08 | 青岛科技大学 | A kind of graft copolymer, the preparation method and application of chitosan and procyanidine |
Non-Patent Citations (5)
| Title |
|---|
| 360化妆品网: "海藻糖对皮肤的作用 海藻糖在化妆品中的五大功效", 《360化妆品网》 * |
| 健客网 HTTPS://M.JIANKE.COM/PRODUCT/796886.HTML?IVK_SA=1024320U: "医用愈肤生物膜水剂活性敷料（蓝科肤宁）", 《健客网》 * |
| 周宜开: "《中华医学百科全书 公共卫生学 环境卫生学》", 31 March 2017, 中国协和医科大学出版社 * |
| 孙蔚凌等: "蓝科肤宁治疗面部激素依赖性皮炎疗效观察", 《临床皮肤科杂志》 * |
| 王建新: "《化妆品植物原料大全》", 30 June 2012, 中国纺织出版社 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN108853312B (en) | Polycinnamic alcohol external gel and preparation method thereof | |
| CN105142728B (en) | Compositions and methods for treating surface wounds | |
| CN109745261B (en) | Scalp care solution and preparation method thereof | |
| CN104434740B (en) | A kind of Chinese medicine blemish clearing gel agent and preparation method thereof | |
| CN111494282B (en) | Red-removing anti-inflammatory oil-controlling acne-removing composition, application thereof and acne-removing balancing essence containing composition | |
| CN109646712B (en) | Colloidal sulfur liquid dressing and preparation method thereof | |
| JPH01503061A (en) | Topical metronidazole preparations | |
| CN113018238A (en) | Anti-bacterial, anti-inflammatory, refreshing and skin-benefiting acne-removing gel and preparation method thereof | |
| CN112472653A (en) | Acne-removing aloe gel and preparation method thereof | |
| CN105641158A (en) | Formula for treating dermatosis | |
| CN111281966A (en) | Composition containing earthworm protein and preparation method and application thereof | |
| CN107468798A (en) | A kind of composition for treating acne and its preparation method and application | |
| CN108078868B (en) | Antiallergic composition for skin care products | |
| CN111840115A (en) | Procyanidine oligomer-based facial hormone-dependent dermatitis treatment liquid and preparation method thereof | |
| CN114146051A (en) | Chinese medicinal gel for promoting granulation and healing ulcer, and its preparation method | |
| EP3373897A1 (en) | Skin care composition | |
| CN113995701B (en) | Composition for removing acnes and acne marks as well as preparation method and application thereof | |
| CN114377054B (en) | Use of cyclocarya paliurus leaves or extracts thereof in preparation of drugs or cosmetics for preventing and/or treating acne | |
| EP3348307A1 (en) | Composition comprising carnitine, sodium cholate, sodium acetate and optionally silver for use in the treatment of psoriasis, vitiligo e rosacea | |
| CN102133324B (en) | Ointment for treating skin burns and scalds | |
| CN107157846A (en) | A kind of anti-acne facial treatment mask | |
| CN101185620A (en) | Cosmetic with youthful-bud-eliminating and beautifying skin-protection function | |
| CN116211781A (en) | Composition for preventing and treating chapped skin, and preparation method and application thereof | |
| CN112076285A (en) | External traditional Chinese medicine composition for treating skin diseases, traditional Chinese medicine preparation and preparation method thereof | |
| CN116135203A (en) | Graphene medical cold compress mask and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| TA01 | Transfer of patent application right |
Effective date of registration: 20210513 Address after: Room 106, No. 3398, Baocheng Road, Beihu science and Technology Development Zone, Changchun City, Jilin Province, 130000 Applicant after: Lanke Yimei science and Technology (Jilin) Co.,Ltd. Address before: 130000 Building 2, 3388 Baocheng Road, Beihu science and Technology Development Zone, Changchun City, Jilin Province Applicant before: Lanke Hengye medical technology (Changchun) Co.,Ltd. |
|
| TA01 | Transfer of patent application right | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20201030 |
|
| RJ01 | Rejection of invention patent application after publication |